
    
      The registry intends to provide real world data on patient characteristics, disease
      management, healthcare utilization, and outcomes in patients with type 2 diabetes and
      established micro- and/or macrovascular disease. Countries involved may vary depending on the
      interest shown by investigators and authorities all over the world
    
  